Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

10
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
10
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

13
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
13
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

17
Body:Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
17
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs01:20

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

7
Body:Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to...
7
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

12
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
12
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

23
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
23

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CT-guided microwave ablation combined with thoracoscopic resection for multiple ground-glass nodules: a single-session treatment strategy.

Frontiers in medicine·2026
Same author

EEG microstates during wake and NREM sleep in insomnia disorder.

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same author

The pyruvate kinase activator etavopivat (FT-4202) limits pulmonary and systemic sequelae of sepsis in a mouse LPS model.

American journal of physiology. Lung cellular and molecular physiology·2026
Same author

The Cognitive benefits of nitrate in patients with alcohol use disorder: unraveling the oral microbiome ectopic colonization pathway.

Molecular psychiatry·2026
Same author

Power Calculation for Non-inferiority Test Based on Linear Combination of Two Correlated Binary Endpoints.

Therapeutic innovation & regulatory science·2026
Same author

Controversial issues in clinical investigation of rare disease drug development.

Journal of biopharmaceutical statistics·2026
Same journal

Updated Recommendations for the Bioanalysis of Antibody-Drug Conjugates (ADC) from the ADC working group of the AAPS Bioanalytical Community.

The AAPS journal·2026
Same journal

In vivo Predictive Dissolution Test Using Biorelevant Bicarbonate Buffer for High-dose Free Acid Drug.

The AAPS journal·2026
Same journal

Whole-Body Pharmacokinetics of Ionizable Lipid, mRNA, and the Expressed Antibody following Intravenous Administration of mRNA-Loaded Lipid Nanoparticles.

The AAPS journal·2026
Same journal

Simple Hydrodynamic Molecular Weight Model for Rapid Assessment of Therapeutic Protein Oligomerization States in Formulation.

The AAPS journal·2026
Same journal

Guiding the Molnupiravir Tablet Formulation Using Physiologically Based Biopharmaceutics Modeling and Successfully Establishing Dissolution Safe Space.

The AAPS journal·2026
Same journal

Correction: Nanotechnology-enhanced Natural Products for Cancer Chemoprevention: Molecular Mechanisms and Clinical Translation.

The AAPS journal·2026
See all related articles

Related Experiment Video

Updated: Oct 11, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.9K

Innovative Design and Analysis for PK/PD Biosimilar Bridging Studies with Multiple References.

Fuyu Song1,2, Xin Zheng3, Yujia Wang4

  • 1Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health, National Clinical Research Center for Mental Disorders, Peking University, Beijing, China.

The AAPS Journal
|December 1, 2021
PubMed
Summary
This summary is machine-generated.

Innovative statistical designs for pharmacokinetic/pharmacodynamic (PK/PD) biosimilar bridging studies are proposed. These methods aim to streamline regulatory submissions by bridging clinical data between regions, potentially avoiding duplicate trials.

Keywords:
BioequivalenceComplete n-of-1 designCrossover trialIncomplete block designMultiple referencesSchuirmann’s two one-sided tests

More Related Videos

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.2K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.3K

Related Experiment Videos

Last Updated: Oct 11, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.9K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.2K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.3K

Area of Science:

  • Pharmacokinetics and Pharmacodynamics
  • Biostatistics
  • Regulatory Science

Background:

  • Biosimilar regulatory submissions often require bridging clinical data between regions when multiple reference products exist.
  • Pharmacokinetic/pharmacodynamic (PK/PD) bridging studies are crucial for leveraging existing clinical data and avoiding redundant trials.
  • Ethnic considerations between regions are important for the validity of bridging studies.

Purpose of the Study:

  • To propose innovative statistical designs for PK/PD biosimilar bridging studies.
  • To investigate statistical models and methods applicable to these novel designs.
  • To provide power analysis for sample size determination using established procedures.

Main Methods:

  • Development of novel statistical designs for PK/PD biosimilar bridging studies.
  • Application of statistical modeling and methods to the proposed designs.
  • Power analysis using Schuirmann's two one-sided tests procedure.
  • Comparative analysis with pairwise testing via simulation.

Main Results:

  • Proposed innovative statistical designs for PK/PD biosimilar bridging studies.
  • Statistical models and methods evaluated for the proposed designs.
  • Power analysis derived and compared to existing methods through simulation.

Conclusions:

  • The proposed statistical designs offer innovative approaches for PK/PD biosimilar bridging studies.
  • The study provides a framework for statistical modeling and power analysis in this context.
  • These methods support efficient biosimilar regulatory submissions by bridging clinical data across regions.